Celldex (CLDX) Posts Q3 Loss of $0.08/Share
More News related to CLDX
- Mentor Capital Cancer Index Start Oversubscribed
- Mentor Capital Takes Investment Position in Each of 10 Cancer Immunotherapy Index Companies
- Mentor Capital's Cancer Immunotherapy Index Closes 2009 with 85% Annualized Gains
- Mentor Capital Announces Plan for New 2010 Actively Managed Cancer Immunotherapy Index and 45 Day Call on C Warrants for CI Index Seed Funding
- Celldex (CLDX) Reports Positive Phase 2 of CDX-011 on Various Breast Cancers
More News related to Earnings
- HNI Corporation (HNI) Tops Q1 EPS by 2c; Revs Light
- Team Health (TMH) Reports Mixed Q4 Results
- Baidu (BIDU) Blows the Lid Off Q4, Shares Jump
- Aspen Insurance (AHL) Posts Q4 adj.-EPS of $1.44, Tops Views
- Acadia Realty Trust (AKR) Misses Q4 FFO by 1c; Guides Below for FY10
Celldex Therapeutics, Inc. (NASDAQ: CLDX) reports Q3 loss of $0.08, versus the analyst estimate of ($0.56).
Related Categories
EarningsStocks Mentioned
+0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
